In July 2022, the FDAs Pharmacy Compounding Advisory Committee (PCAC) voted against inclusion of enclomiphene citrate on the final 503A bulks list, though the material remains listed as category 1 on the most recent iteration of the 503A bulk drugs list
TB-500 does not have an FDA-approved dosage because it is not FDA-approved as a drug
The current public schedule is: TRIUMPH-1: general obesity, 80-week treatment duration, the largest TRIUMPH trial, pivotal for the NDA filing
Mitochondrial ROS prime the hyperglycemic shift from apoptosis to necroptosis
Borowsky, Li.-chong Wang, Terry K
Benefits May reduce visceral fat, enhance muscle definition, support cognitive health, improve metabolism, and promote overall vitality